Article
Oncology
Alan L. Ho, Irene Brana, Robert Haddad, Jessica Bauman, Keith Bible, Sjoukje Oosting, Deborah J. Wong, Myung-Ju Ahn, Valentina Boni, Caroline Even, Jerome Fayette, Maria Jose Flor, Kevin Harrington, David S. Hong, Sung-Bae Kim, Lisa Licitra, Ioanna Nixon, Nabil F. Saba, Stephan Hackenberg, Pol Specenier, Francis Worden, Binaifer Balsara, Mollie Leoni, Bridget Martell, Catherine Scholz, Antonio Gualberto
Summary: This study evaluated the efficacy of Tipifarnib in patients with HRAS mutations in R/M HNSCC, showing an objective response rate of 55% in high-VAF HNSCC patients. Tipifarnib demonstrated longer progression-free survival and overall survival compared to previous therapies, with the most frequent treatment-emergent adverse events being anemia and lymphopenia.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Sehrish Javaid, Antje Schaefer, Craig M. Goodwin, Victoria V. Nguyen, Frances L. Massey, Mariaelena Pierobon, Da'jhnae Gambrell-Sanders, Andrew M. Waters, Kathryn N. Lambert, J. Nathaniel Diehl, G. Aaron Hobbs, Kris C. Wood, Emanuel F. Petricoin, Channing J. Der, Adrienne D. Cox
Summary: HPV-negative head and neck squamous cell carcinoma (HNSCC) is a common cancer with limited treatment options. This study investigated the potential of the farnesyltransferase inhibitor tipifarnib as a therapeutic strategy for HRAS-mutant HNSCC. The results suggest that tipifarnib shows promise in targeting HRAS and its effector signaling, and combination treatments may enhance its effectiveness.
MOLECULAR CANCER THERAPEUTICS
(2022)
Review
Biochemistry & Molecular Biology
Sindhu Nair, James A. Bonner, Markus Bredel
Summary: EGFR is overexpressed in head and neck squamous cell carcinoma and anti-EGFR strategies have shown some clinical benefit but often lead to resistance. Mutations in various domains of the EGFR gene can impact drug binding, radiation response, and overall survival in HNSCC patients. Understanding the EGFR mutational landscape and its effects on treatment resistance can help stratify patients for targeted therapies and maximize therapeutic benefits.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Sankar Jagadeeshan, Manu Prasad, Mai Badarni, Talal Ben-Lulu, Vijayasteltar Belsamma Liju, Sooraj Mathukkada, Claire Saunders, Avital Beeri Shnerb, Jonathan Zorea, Ksenia M. Yegodayev, Monica Wainer, Liza Vtorov, Irit Allon, Ofir Cohen, Gro Gausdal, Dinorah Friedmann-Morvinski, Sok Ching Cheong, Alan L. Ho, Ari J. Rosenberg, Linda Kessler, Francis Burrows, Dexin Kong, Jennifer R. Grandis, J. Silvio Gutkind, Moshe Elkabets
Summary: The presence of mutated HRAS in head and neck cancer patients is associated with poor prognosis and high metastasis rate. Mutated HRAS promotes cancer cell invasion and metastasis by suppressing the Hippo pathway and promoting AXL expression. The use of tipifarnib, a farnesyltransferase inhibitor, can activate the Hippo pathway, suppress metastasis, and regulate angiogenesis in HNC.
Review
Biochemistry & Molecular Biology
Ajaz A. Bhat, Parvaiz Yousuf, Nissar A. Wani, Arshi Rizwan, Shyam S. Chauhan, Mushtaq A. Siddiqi, Davide Bedognetti, Wael El-Rifai, Michael P. Frenneaux, Surinder K. Batra, Mohammad Haris, Muzafar A. Macha
Summary: HNSCC is a highly aggressive disease with a poor prognosis, and understanding the complex TME interactions is crucial for new therapeutic interventions. The different molecular and immune landscapes between HPV+ve and HPV-ve tumors present new opportunities for individualized, targeted CIT regimens.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Review
Biochemistry & Molecular Biology
Ching-Yun Hsieh, Ching-Chan Lin, Wei-Chao Chang
Summary: Taxanes, especially docetaxel, are widely used in combination therapy for head and neck squamous cell carcinoma (HNSCC) and have shown advantages in improving patient outcomes. Taxanes not only function as antimitotics, but also impair various oncogenic signaling pathways. However, the development of drug resistance remains a major obstacle to treatment response.
Review
Medicine, Research & Experimental
Danni Li, Xuran Li, Jun Zhao, Fei Tan
Summary: Molecular imaging has the potential to play a role in the diagnosis of head and neck squamous cell carcinoma, and early tumor identification can help with treatment. Targeted therapy has already been proven effective in some cases.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Cell Biology
Qi Chen, Ling Chu, Xinyu Li, Hao Li, Ying Zhang, Qingtai Cao, Quan Zhuang
Summary: This study established a prediction model related to fibrosis, hypoxia, and glycolysis for evaluating the prognosis and immune infiltration in head and neck squamous cell carcinoma (HNSCC) patients. Six genes associated with risk stratification were identified, and key immune cells were found to differ between high and low-risk groups. The model provides risk assessment for better prognoses in HNSCC patients.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Review
Oncology
Anna Brandt, Benjamin Thiele, Christoph Schultheiss, Eveline Daetwyler, Mascha Binder
Summary: Tumors release cell-free DNA (cfDNA) into the bloodstream, and liquid biopsies have become a non-invasive diagnostic test to analyze cfDNA and monitor cancer progression. This technique is particularly useful in patients with head and neck squamous cell carcinoma (HNSCC) due to its genetic heterogeneity and limited imaging sensitivity. However, there are technical challenges that need to be addressed before widespread clinical application of liquid biopsy in HNSCC management.
Review
Oncology
Jiayu Wang, Dana Al-Majid, J. Chad Brenner, Joshua D. Smith
Summary: Head and neck squamous cell carcinomas (HNSCCs) have limited treatment options for patients with recurrent and/or metastatic disease (R/M HNSCC), and the development of new precision medicine strategies is crucial. HRAS proto-oncogene alterations occur in 4-8% of R/M HNSCC tumors, and recent advancements have been made in the use of farnesyltransferase inhibitors to target HRAS signaling. This review focuses on the biology of HRAS signaling in HNSCC, and the rationale and outcomes of farnesyltransferase inhibitors in HRAS-mutant tumors.
Article
Dentistry, Oral Surgery & Medicine
Bernhard J. Jank, Julia Schnoell, Katharina Kladnik, Carmen Sparr, Markus Haas, Elisabeth Gurnhofer, Alexander L. Lein, Markus Brunner, Lukas Kenner, Lorenz Kadletz-Wanke, Gregor Heiduschka
Summary: This study explored the role of the TGF-β pathway in HNSCC and evaluated the antineoplastic and radiosensitizing effects of the TGFBR1 inhibitor, vactosertib, in vitro.
Review
Biochemistry & Molecular Biology
Xin Zhou, Xiaoshen Wang
Summary: This review provides a detailed illustration of the biology, genomic features, and immune landscapes of HPV-associated HNSCC, supporting the synergistic effect of radioimmunotherapy. Current evidence and ongoing clinical trials suggest the potential of radioimmunotherapy in recurrent/metastatic or definitive settings. Future challenges include optimization of radiotherapy and the incorporation of novel therapeutic options.
Review
Medicine, General & Internal
Kamila Romanowska, Agnieszka Sobecka, Agnieszka A. Rawluszko-Wieczorek, Wiktoria M. Suchorska, Wojciech Golusinski
Summary: Head and neck squamous carcinoma (HNSCC) is the sixth most prevalent cancer worldwide, with molecular pathogenesis involving cell cycle disorders, intercellular signaling, proliferation, squamous cell differentiation, and apoptosis. In addition to genetic mutations, epigenetic alterations such as DNA methylation and histone modifications play a key role in promoting cancer formation and progression, making them potential biomarkers and therapeutic targets for HNSCC.
Review
Medicine, Research & Experimental
Hanlin Hu, Bo Li, Junke Wang, Ye Tan, Mingjin Xu, Wenhua Xu, Haijun Lu
Summary: Head and neck squamous cell carcinoma (HNSCC) is influenced by various factors and cisplatin resistance is a major concern. This review focuses on the roles of cancer stem cells and autophagy in cisplatin resistance and discusses potential treatment strategies, including nanodrug delivery systems targeting cancer stem cells or autophagy. The review also highlights the prospects and challenges associated with nanodelivery platforms in addressing cisplatin resistance in HNSCC.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Oncology
Usha Patel, Sadhana Kannan, Swapnil U. Rane, Neha Mittal, Poonam Gera, Asawari Patil, Subhakankha Manna, Vishwayani Shejwal, Vanita Noronha, Amit Joshi, Vijay M. Patil, Kumar Prabhash, Manoj B. Mahimkar
Summary: This study identifies CD44 and CD44v6 as potential predictive biomarkers for NCRT response in HPV-negative LA-HNSCC patients, and CD98hc as an independent negative prognostic biomarker. These findings can help identify which HNSCC patients are most suitable for specific treatments.
BRITISH JOURNAL OF CANCER
(2022)
Article
Endocrinology & Metabolism
Jae Hoon Moon, Chang Hwan Ryu, Sun Wook Cho, June Young Choi, Eun-Jae Chung, Jeong Hun Hah, Yul Hwangbo, Woo-Jin Jeong, Yuh-Seog Jung, Ji-Hoon Kim, Min Joo Kim, Su-Jin Kim, Yeo Koon Kim, Chang Yoon Lee, Eun Kyung Lee, Ji Ye Lee, Kyu Eun Lee, You Jin Lee, Yumi Lee, Hyeong Won Yu, Do Joon Park, Junsun Ryu, Young Joo Park
Summary: The study found that for patients with low-risk PTMC, choosing active surveillance may have a positive impact on quality of life over a 2-year period.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Multidisciplinary Sciences
Shunichiro Tsukamoto, Hiromichi Wakui, Kengo Azushima, Takahiro Yamaji, Shingo Urate, Toru Suzuki, Eriko Abe, Shohei Tanaka, Shinya Taguchi, Takayuki Yamada, Sho Kinguchi, Daisuke Kamimura, Akio Yamashita, Daisuke Sano, Masayuki Nakano, Tatsuo Hashimoto, Kouichi Tamura
Summary: The study found that renal ACE2 expression significantly decreased in chronic kidney disease models, but pulmonary expression remained unaffected. Treatment with the RAS blocker olmesartan attenuated urinary albumin excretion in adenine mice, without affecting renal or pulmonary ACE2 expression levels.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Goshi Nishimura, Daisuke Sano, Yasuhiro Arai, Hideaki Takahashi, Takashi Hatano, Yosuke Kitani, Kentaro Takada, Takashi Wada, Yohei Hiiragi, Nobuhiko Oridate
Summary: Hypopharyngeal cancer patients treated with transoral surgery had a higher risk of newly diagnosed secondary cancers compared to patients with other cancers, with the risk being 3.60 times higher. The 3-year survival rates were high, but hypopharyngeal cancer patients were more likely to develop new secondary cancers during follow-up.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Ryuji Yasumatsu, Yasushi Shimizu, Nobuhiro Hanai, Shin Kariya, Tomoya Yokota, Takashi Fujii, Kiyoaki Tsukahara, Mizuo Ando, Kenji Hanyu, Tsutomu Ueda, Hitoshi Hirakawa, Shunji Takahashi, Takeharu Ono, Daisuke Sano, Moriyasu Yamauchi, Akihito Watanabe, Koichi Omori, Tomoko Yamazaki, Nobuya Monden, Naomi Kudo, Makoto Arai, Syuji Yonekura, Takahiro Asakage, Takahiro Nekado, Takayuki Yamada, Akihiro Homma
Summary: The study demonstrated the long-term effectiveness of nivolumab in patients with recurrent or metastatic head and neck cancer in real-world setting, as well as the potential effectiveness of subsequent chemotherapy. Safety profile remained consistent with that observed in the 1-year follow-up.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Nutrition & Dietetics
Yuraporn Sahasakul, Wannee Angkhasirisap, Aroonwan Lam-Ubol, Amornrat Aursalung, Daisuke Sano, Kentaro Takada, Dunyaporn Trachootham
Summary: This study found that substituting glucose with xylitol can slow down tumor growth, prolong survival time, and inhibit the expression of glycolytic enzymes. This discovery provides a basis for considering xylitol as a sweetener in food products for cancer survivors.
Article
Environmental Sciences
Young Ju Jin, Jeong Hun Hah, Mi Jung Kwon, Ji Hee Kim, Joo-Hee Kim, Sung-Kyun Kim, Bumjung Park, Hyo Geun Choi
Summary: This study evaluated the differences in body mass index (BMI) and blood pressure between Korean adults who underwent thyroidectomy and a comparison group. The results showed that diastolic blood pressure was significantly lower after thyroidectomy in both thyroid cancer patients and the comparison group. However, the overall BMI, systolic blood pressure, and diastolic blood pressure did not show significant differences between the thyroidectomy group and the matched comparison group.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Article
Endocrinology & Metabolism
Yul Hwangbo, June Young Choi, Eun Kyung Lee, Chang Hwan Ryu, Sun Wook Cho, Eun-Jae Chung, Jeong Hun Hah, Woo-Jin Jeong, Sue K. Park, Yuh-Seog Jung, Ji-Hoon Kim, Min Joo Kim, Su-Jin Kim, Yeo Koon Kim, Chang Yoon Lee, Ji Ye Lee, You Jin Lee, Hyeong Won Yu, Do Joon Park, Junsun Ryu, Young Joo Park, Kyu Eun Lee, Jae Hoon Moon
Summary: The study identified factors associated with the choice of active surveillance (AS) for patients with low-risk papillary thyroid microcarcinoma (PTMC) including patient age, tumor size, consultation with an endocrinologist, and use of a decision aid. Patients in the AS group were more influenced by information from the media, while those in the immediate surgery (iOP) group were more influenced by family members.
Article
Oncology
Daisuke Sano, Motohiko Tokuhisa, Hideaki Takahashi, Takashi Hatano, Goshi Nishimura, Yasushi Ichikawa, Nobuhiko Oridate
Summary: This Japanese retrospective cohort study evaluated the real-world therapeutic outcomes of pembrolizumab or pembrolizumab plus chemotherapy as first-line therapy for patients with recurrent/metastatic squamous cell carcinoma of the head and neck. The study found that the observed therapeutic efficacy and safety of pembrolizumab in real-world clinical practice was consistent with the data of the KEYNOTE-048 trial.
ANTICANCER RESEARCH
(2022)
Article
Otorhinolaryngology
Meijin Nakayama, Takashi Wada, Yasuhiro Isono, Daisuke Sano, Goshi Nishimura, Nobuhiko Oridate, F. Christopher Holsinger, Ryan Orosco
Summary: This study evaluated the feasibility of narrow-field supracricoid partial laryngectomy with cricohyoidoepiglottopexy (NF-SCPL-CHEP) in five patients with glottic cancers. The results showed that NF-SCPL-CHEP was technically feasible and oncologically sound, with shorter hospitalization time and favorable postoperative recovery. No major complications or local recurrences were observed.
AURIS NASUS LARYNX
(2023)
Article
Otorhinolaryngology
Doh Young Lee, J. Hun Hah, Woo-Jin Jeong, Eun-Jae Chung, Tack-Kyun Kwon, Soon-Hyun Ahn, Myung-Whun Sung, Seong Keun Kwon
Summary: This study aimed to assess the genetic differences between cases of early-stage tongue cancer that were positive or negative for lymph node metastasis. It was found that defensin may be a novel biomarker for early regional metastasis in T1/2 tongue cancer.
CLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY
(2022)
Article
Oncology
Yoshihiro Aizawa, Kentaro Takada, Jun Aoyama, Daisuke Sano, Shoji Yamanaka, Masahide Seki, Yuta Kuze, Jordan A. A. Ramilowski, Ryo Okuda, Yasuharu Ueno, Yusuke Nojima, Yoshiaki Inayama, Hiromitsu Hatakeyama, Takashi Hatano, Hideaki Takahashi, Goshi Nishimura, Satoshi Fujii, Yutaka Suzuki, Hideki Taniguchi, Nobuhiko Oridate
Summary: This study successfully generated experimental models of multiple histological subtypes of salivary gland carcinoma (SGC) using patient-derived xenograft (PDX) and organoid culture techniques. These models recapitulated the histological and genetic characteristics of the original tumors, providing a valuable resource for the development of novel therapeutic strategies and investigation of the molecular mechanisms underlying these malignancies.
Review
Oncology
Yuki Saito, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Ichiro Ota, Tomoya Yokota, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Kaoru Tanaka, Takuma Onoe, Susumu Okano, Yoshinori Imamura, Yosuke Ariizumi, Ryuichi Hayashi
Summary: This article discusses the clinical trials and prevention of human papillomavirus-related oropharyngeal carcinoma in Japan. It emphasizes the increasing incidence of the disease and the importance of surgical treatment for eligible patients undergoing chemotherapy and radiation.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Yoshinori Imamura, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Ichiro Ota, Yuki Saito, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Tomoya Yokota, Susumu Okano, Kaoru Tanaka, Takuma Onoe, Yosuke Ariizumi, Akihiro Homma
Summary: Salivary gland malignancies are rare tumors with diverse histological and biological features. The application of systemic therapy in the treatment of salivary gland malignancies remains challenging, and there is currently no defined treatment advantage. Personalized therapies have been widely accepted, but a multidisciplinary approach is necessary to consider both patient needs and tumor characteristics.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Susumu Okano, Akihiro Homma, Naomi Kiyota, Makoto Tahara, Nobuhiro Hanai, Takahiro Asakage, Kazuto Matsuura, Takenori Ogawa, Yuki Saito, Daisuke Sano, Takeshi Kodaira, Atsushi Motegi, Koichi Yasuda, Shunji Takahashi, Kaoru Tanaka, Takuma Onoe, Tomoya Yokota, Yoshinori Imamura, Yosuke Ariizumi, Tetsuo Akimoto, Ryuichi Hayashi
Summary: Induction chemotherapy is a treatment option for head and neck squamous cell carcinoma, with the current standard regimen being docetaxel, cisplatin and 5-FU. Careful consideration should be given to factors such as toxicity, cost, and treatment duration when choosing this therapy, and there is still no consensus on the best treatment option after induction chemotherapy.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
Hideaki Takahashi, Daisuke Sano, Takashi Hatano, Kaname Sato, Tatsu Kuwahara, Yoshihiro Aizawa, Jun Aoyama, Nobuhiko Oridate